News
Depressive therapy Spravato demonstrates superior efficacy
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) has announced results from its ESCAPE-TRD study – a long-term, randomised, open-label phase 3b clinical trial designed to evaluate the short and long-term efficacy, safety and tolerability of Spravato.